A obesidade constitui hoje um preocupante problema de saúde mundial, pois, além de prejudicar o bem estar físico de seu portador, traz consigo comorbidades associadas que aumentam as taxa de morbi-mortalidade. Entre elas incluem-se hipertensão arterial, diabetes mellitus, síndrome da apnéia obstrutiva do sono, osteoartrose, síndrome metabólica e outras. Os recentes avanços alcançados por importantes pesquisas na área molecular conseguiram elucidar grande parte dos mecanismos de controle central do peso corporal, expondo mais um possível sítio para a ação de drogas antiobesidade. A despeito dessas atualidades, o ambiente em que vivemos e determinados comportamentos que seguimos também apresentam forte influência sobre nosso balanço energético e peso corporal, tornando impossível tratar a obesidade por apenas uma frente de ataque. A atividade física e as mudanças no estilo de vida continuam sendo as medidas iniciais da terapêutica e, após estabelecerem-se estas condutas, as recentes descobertas na terapêutica medicamentosa passam a ter valia na tentativa de conter esta epidemia.

Background: Ketamine intravenous infusion has been used safely to several chronic pains and it is a good option to refractory chronic headaches. It is a noncompetitive NMDA receptor antagonist that blocks glutamate, responsible for the dissociation between thalamus-neocortical and limbic systems, leading to changes in patients’ pain perception. Due to this theorical mechanism and results in reducing cortical spreading depression, Ketamine has been proposed as a treatment for migraine. Methods: We conducted a retrospective medical chart review study at Hospital Israelita Albert Einstein including three patients. All of them were diagnosed previosly with refractory chronic headache. Results: Of participants included (n = 3), two were woman. The median duration of the disease was 21 years and 12 previous treatment’s failures. All the patients were currently in use of more than 4 preventive drugs. Treatment-emergent response was seen in all patients, requiring 1, 3 and 4 sessions to complete plain remission. They presented good tolerability to the treatment. One patient complained of tinnitus and mild dizziness at the end of the last session, which lasted less than 30 minutes. Conclusion: Ketamine is well tolerated and an effective treatment for patients with refractory chronic headache.

No abstract

No abstract